Greenwood Village, CO, May 7, 2014 — After a nationwide search, Rocky Mountain Cancer Centers (RMCC) has named Glenn Balasky as its Executive Director. Balasky was most recently at Cardinal Health and Executive Director of The Mark H. Zangmeister Center, a cancer center in Columbus, OH. He was with the Zangmeister Center for 10 years and oversaw all aspects of practice operations on behalf of the physician partners. Prior to that he was a Project Director with Denver based OpTx Corporation and managed the implementation of oncology specific electronic medical record conversions for Duke University Medical Center and the Washington Cancer Institute. OpTx was acquired by Varian Medical Systems in 2004.
“Glenn has extensive healthcare management experience that we believe will serve Rocky Mountain Cancer Centers well moving forward,” says Dr. John Fleagle, one of the founding partners and current president of RMCC’s physician partnership board. “We are pleased to welcome him back to Colorado and excited for the expertise he will bring to our organization.” Balasky will start with RMCC on May 19 and will be based out of the organization’s central business office in Greenwood Village.
Rocky Mountain Cancer Centers began in the early 1990s as a small group practice of six physicians with a new approach to treating cancer—administering chemotherapy on an outpatient basis. RMCC has since developed into a premier oncology network in Colorado, with 19 community-based locations across the state and 58 physicians among its more than 600 employees. From clinical trials to the latest in radiation technology to nationally recognized psychosocial support programs, RMCC provides advanced care to patients with all types of cancers and blood disorders.
Rocky Mountain Cancer Centers is united in healing with The US Oncology Network, one of the nation’s largest networks of integrated community-based oncology practices dedicated to advancing high-quality, evidence-based cancer care. As an affiliate of The US Oncology Network, RMCC is united with nearly 1,000 physicians nationwide. Rocky Mountain Cancer Centers participates in clinical trials through US Oncology Research, which has played a role in 48 FDA-approved cancer therapies, nearly one-third of all cancer therapies approved by the FDA to date. For more information, visit www.usoncology.com.